CRDF
NASDAQ
US
Cardiff Oncology, Inc. - Common Stock
$1.58
▼ $-0.03
(-1.86%)
Vol 529K
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$189.3M
ROE
-77.5%
Margin
-10106.8%
D/E
0.00
Beta
1.32
52W
$2–$5
Wall Street Consensus
14 analysts · Apr 20263
Strong Buy
9
Buy
2
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
PEPG
PepGen Inc
$447.6M
GNLX
Genelux Corp
$165.9M
SGMO
Sangamo Therapeutics Inc
$141.3M
BMEA
Biomea Fusion Inc
$87.7M
KPTI
Karyopharm Therapeutics Inc
$125.5M
CADL
Candel Therapeutics Inc
$310.2M
ALDX
Aldeyra Therapeutics Inc
$99.9M
SPRB
Spruce Biosciences, Inc
$93.2M
COYA
Coya Therapeutics Inc
$121.4M
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.19 | $-0.11 | +$0.08 |
| Sep 2025 | $-0.21 | $-0.17 | +$0.04 |
| Jun 2025 | $-0.20 | $-0.21 | $-0.01 |
| Mar 2025 | $-0.19 | $-0.20 | $-0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $151K | $109K | $121K | $120K | $243K |
| Net Income | — | -$11.8M | -$13.4M | -$13.9M | -$11.3M | -$7.2M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -78.6% | -77.9% | -77.9% | -77.9% | -77.2% | -77.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -11523.1% | -9344.1% | -9344.1% | -9344.1% | -10064.3% | -10106.8% |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 4.42 | 4.42 | 4.42 | 4.42 | 4.20 | 4.20 |
Key Ratios
ROA (TTM)
-63.0%
P/S (TTM)
377.81
P/B
3.5
EPS (TTM)
$-0.80
CF/Share
$-0.91
Rev Growth 3Y
+23.8%
52W High
$4.99
52W Low
$1.90
$1.90
52-Week Range
$4.99
Financial Health
Free Cash Flow
-$6.0M
Net Debt
-$16.6M
Cash
$17.5M
Total Debt
$832K
As of Dec 31, 2025
How does CRDF compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CRDF valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
377.8
▲
2840%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
3.5
▲
41%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CRDF profitability vs Biotechnology peers
ROE
-77.5%
▼
15%
below
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
-10106.8%
▼
3425%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
100.0%
▲
27%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-63.0%
▼
35%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
CRDF financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
4.2
▼
5%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
1.3
▲
36%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
CRDF fundamentals radar
CRDF
Peer median
Industry
CRDF profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CRDF vs peers: key metrics
Top Holders
Top 5: 21.62%Blackrock Inc.
5.91%
$6.3M
Vanguard Group Inc
5.44%
$5.8M
Laurion Capital Management,…
3.87%
$4.1M
Pfizer Inc
3.53%
$3.7M
Acorn Capital Advisors, LLC…
2.87%
$3.0M
As of Dec 31, 2025
Latest News
No related news yet